An open-label, multicenter Phase 1b/2 dose-ranging study to assess the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of SRA737 in combination with niraparib in patients with mCRPC

Trial Profile

An open-label, multicenter Phase 1b/2 dose-ranging study to assess the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of SRA737 in combination with niraparib in patients with mCRPC

Planning
Phase of Trial: Phase I/II

Latest Information Update: 27 Feb 2018

At a glance

  • Drugs Niraparib (Primary) ; SRA 737 (Primary)
  • Indications Prostate cancer
  • Focus Adverse reactions
  • Sponsors Sierra Oncology
  • Most Recent Events

    • 27 Feb 2018 According to a Sierra Oncology Inc. media release, Professor Johann de Bono, Regius Professor of Cancer Research at The Institute of Cancer Research, London, and Consultant Medical Oncologist at The Royal Marsden NHS Foundation Trust, will be the Chief Investigator of this study.
    • 27 Feb 2018 According to a Sierra Oncology Inc. media release, this trial is expected to commence in the fourth quarter of 2018.
    • 13 Nov 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top